Zeltia SA is a biopharmaceutical company, which specialized in the development of marine-based drugs for use in oncology.
The company operates through two main segments: Biopharmaceuticals and Consumer Chemicals.
The Biopharmaceuticals segment engages in the research, development and marketing of antitumor drugs through Pharma Mar SAU, the development and marketing of diagnosis kits through Genómica SAU and the development of therapies based on reducing or silencing gene expression through Sylentis SA. The Consumer Chemicals segment produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products through various subsidiaries, which include Zelnova SA, Xylazel SA and Copyr SpA. Zeltia was founded on August 3, 1939 and is headquartered in Madrid, Spain.